Back to today’s briefing

Story perspectives

Craig Hallum Rates Myriad Genetics a 'Buy' at $29

2/13/2025

49 7

Summary

Story summary

Craig Hallum has launched coverage on Myriad Genetics (NASDAQ:MYGN), giving it a promising "buy" rating and a price target of $29, suggesting a remarkable 125% upside. While the consensus among other analysts leans towards a "Hold" with a target of $22.54, Myriad Genetics continues to make strides in the genetic testing field, boasting a market cap of $1.17 billion.

1 of 1

Story summary

Craig Hallum has launched coverage on Myriad Genetics (NASDAQ:MYGN), giving it a promising "buy" rating and a price target of $29, suggesting a remarkable 125% upside. While the consensus among other analysts leans towards a "Hold" with a target of $22.54, Myriad Genetics continues to make strides in the genetic testing field, boasting a market cap of $1.17 billion.